Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 319

1.

The composition of contemporary American and Swedish smokeless tobacco products.

McAdam KG, Kimpton H, Faizi A, Porter A, Rodu B.

BMC Chem. 2019 Mar 19;13(1):31. doi: 10.1186/s13065-019-0548-0. eCollection 2019 Dec.

2.

Acetoin is a precursor to diacetyl in e-cigarette liquids.

Vas CA, Porter A, McAdam K.

Food Chem Toxicol. 2019 Nov;133:110727. doi: 10.1016/j.fct.2019.110727. Epub 2019 Aug 1.

3.

Use of social media to establish vapers puffing behaviour: Findings and implications for laboratory evaluation of e-cigarette emissions.

McAdam K, Warrington A, Hughes A, Adams D, Margham J, Vas C, Davis P, Costigan S, Proctor C.

Regul Toxicol Pharmacol. 2019 Oct;107:104423. doi: 10.1016/j.yrtph.2019.104423. Epub 2019 Jul 13.

4.

Investigation of number of replicate measurements required to meet cigarette smoke chemistry regulatory requirements measured under Canadian intense smoking conditions.

Eldridge A, Betson T, Gama MV, Errington G, McAdam K.

Regul Toxicol Pharmacol. 2019 Oct;107:104402. doi: 10.1016/j.yrtph.2019.06.001. Epub 2019 Jun 12.

5.

Agents of change among people living with HIV and their social networks: stepped-wedge randomised controlled trial of the NAMWEZA intervention in Dar es Salaam, Tanzania.

Smith Fawzi MC, Siril H, Liu Y, McAdam K, Ainebyona D, McAdam E, Somba M, Oljemark K, Mleli N, Lienert J, Andrew I, Haberlen S, Simwinga A, Todd J, Makongwa S, Li N, Kaaya S.

BMJ Glob Health. 2019 May 9;4(3):e000946. doi: 10.1136/bmjgh-2018-000946. eCollection 2019.

6.

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.

Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA; PERSEPHONE Steering Committee and Trial Investigators.

Lancet. 2019 Jun 29;393(10191):2599-2612. doi: 10.1016/S0140-6736(19)30650-6. Epub 2019 Jun 6.

7.

Analysis of coumarin and angelica lactones in smokeless tobacco products.

McAdam K, Enos T, Goss C, Kimpton H, Faizi A, Edwards S, Wright C, Porter A, Rodu B.

Chem Cent J. 2018 Dec 20;12(1):142. doi: 10.1186/s13065-018-0506-2.

8.

Influence of machine-based puffing parameters on aerosol and smoke emissions from next generation nicotine inhalation products.

McAdam K, Davis P, Ashmore L, Eaton D, Jakaj B, Eldridge A, Liu C.

Regul Toxicol Pharmacol. 2019 Feb;101:156-165. doi: 10.1016/j.yrtph.2018.11.006. Epub 2018 Nov 13.

PMID:
30445136
9.

Fractionation of cadmium in tobacco and cigarette smoke condensate using XANES and sequential leaching with ICP-MS/MS.

Cuello-Nuñez S, Benning J, Liu C, Branton P, Hu J, McAdam KG, Coburn S, Braybrook J, Goenaga-Infante H.

Anal Bioanal Chem. 2018 Oct;410(26):6795-6806. doi: 10.1007/s00216-018-1265-6. Epub 2018 Aug 10.

PMID:
30094791
10.

Ethyl carbamate in Swedish and American smokeless tobacco products and some factors affecting its concentration.

McAdam K, Vas C, Kimpton H, Faizi A, Liu C, Porter A, Synnerdahl T, Karlsson P, Rodu B.

Chem Cent J. 2018 Jul 24;12(1):86. doi: 10.1186/s13065-018-0454-x.

11.

Evaluation of flavourings potentially used in a heated tobacco product: Chemical analysis, in vitro mutagenicity, genotoxicity, cytotoxicity and in vitro tumour promoting activity.

Crooks I, Neilson L, Scott K, Reynolds L, Oke T, Forster M, Meredith C, McAdam K, Proctor C.

Food Chem Toxicol. 2018 Aug;118:940-952. doi: 10.1016/j.fct.2018.05.058. Epub 2018 Jun 4.

PMID:
29879435
12.

Reply to Jacob and Colebunders.

Ellenberg SS, Keusch GT, Babiker AG, Edwards KM, Lewis RJ, Lundgren JD, Wells CD, Wabwire-Mangen F, McAdam KPWJ.

Clin Infect Dis. 2018 Aug 31;67(6):985-986. doi: 10.1093/cid/ciy250. No abstract available.

PMID:
29590323
13.

Integrating chemical, toxicological and clinical research to assess the potential of reducing health risks associated with cigarette smoking through reducing toxicant emissions.

McAdam K, Murphy J, Eldridge A, Meredith C, Proctor C.

Regul Toxicol Pharmacol. 2018 Jun;95:102-114. doi: 10.1016/j.yrtph.2018.03.005. Epub 2018 Mar 9.

14.

Comprehensive survey of radionuclides in contemporary smokeless tobacco products.

McAdam K, Kimpton H, Porter A, Liu C, Faizi A, Mola M, McAughey J, Rodu B.

Chem Cent J. 2017 Dec 19;11(1):131. doi: 10.1186/s13065-017-0359-0.

15.

Rigorous Clinical Trial Design in Public Health Emergencies Is Essential.

Ellenberg SS, Keusch GT, Babiker AG, Edwards KM, Lewis RJ, Lundgren JD, Wells CD, Wabwire-Mangen F, McAdam KPWJ.

Clin Infect Dis. 2018 Apr 17;66(9):1467-1469. doi: 10.1093/cid/cix1032.

16.

In search of global governance for research in epidemics.

Peters DH, Keusch GT, Cooper J, Davis S, Lundgren J, Mello MM, Omatade O, Wabwire-Mangen F, McAdam KPWJ.

Lancet. 2017 Oct 7;390(10103):1632-1633. doi: 10.1016/S0140-6736(17)32546-1. Epub 2017 Oct 5. No abstract available.

PMID:
29131784
17.

Assessment of tobacco heating product THP1.0. Part 9: The placement of a range of next-generation products on an emissions continuum relative to cigarettes via pre-clinical assessment studies.

Murphy J, Liu C, McAdam K, Gaҫa M, Prasad K, Camacho O, McAughey J, Proctor C.

Regul Toxicol Pharmacol. 2018 Mar;93:92-104. doi: 10.1016/j.yrtph.2017.10.001. Epub 2017 Oct 25.

18.

Assessment of tobacco heating product THP1.0. Part 2: Product design, operation and thermophysical characterisation.

Eaton D, Jakaj B, Forster M, Nicol J, Mavropoulou E, Scott K, Liu C, McAdam K, Murphy J, Proctor CJ.

Regul Toxicol Pharmacol. 2018 Mar;93:4-13. doi: 10.1016/j.yrtph.2017.09.009. Epub 2017 Oct 25.

19.

Assessment of novel tobacco heating product THP1.0. Part 3: Comprehensive chemical characterisation of harmful and potentially harmful aerosol emissions.

Forster M, Fiebelkorn S, Yurteri C, Mariner D, Liu C, Wright C, McAdam K, Murphy J, Proctor C.

Regul Toxicol Pharmacol. 2018 Mar;93:14-33. doi: 10.1016/j.yrtph.2017.10.006. Epub 2017 Oct 25.

20.

Assessing modified risk tobacco and nicotine products: Description of the scientific framework and assessment of a closed modular electronic cigarette.

Murphy J, Gaca M, Lowe F, Minet E, Breheny D, Prasad K, Camacho O, Fearon IM, Liu C, Wright C, McAdam K, Proctor C.

Regul Toxicol Pharmacol. 2017 Nov;90:342-357. doi: 10.1016/j.yrtph.2017.09.008. Epub 2017 Sep 25. Review.

21.

Clinical trials during epidemics.

Keusch GT, McAdam KPWJ.

Lancet. 2017 Jun 24;389(10088):2455-2457. doi: 10.1016/S0140-6736(17)31602-1. No abstract available.

PMID:
28656892
22.

A novel hybrid tobacco product that delivers a tobacco flavour note with vapour aerosol (Part 1): Product operation and preliminary aerosol chemistry assessment.

Poynton S, Sutton J, Goodall S, Margham J, Forster M, Scott K, Liu C, McAdam K, Murphy J, Proctor C.

Food Chem Toxicol. 2017 Aug;106(Pt A):522-532. doi: 10.1016/j.fct.2017.05.022. Epub 2017 May 30.

23.

Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial.

Thomas JSJ, Provenzano E, Hiller L, Dunn J, Blenkinsop C, Grybowicz L, Vallier AL, Gounaris I, Abraham J, Hughes-Davies L, McAdam K, Chan S, Ahmad R, Hickish T, Houston S, Rea D, Caldas C, Bartlett JM, Cameron DA, Hayward RL, Earl HM.

Mod Pathol. 2017 Aug;30(8):1069-1077. doi: 10.1038/modpathol.2017.30. Epub 2017 May 26.

24.

Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.

Earl HM, Hiller L, Howard HC, Dunn JA, Young J, Bowden SJ, McDermaid M, Waterhouse AK, Wilson G, Agrawal R, O'Reilly S, Bowman A, Ritchie DM, Goodman A, Hickish T, McAdam K, Cameron D, Dodwell D, Rea DW, Caldas C, Provenzano E, Abraham JE, Canney P, Crown JP, Kennedy MJ, Coleman R, Leonard RC, Carmichael JA, Wardley AM, Poole CJ; tAnGo trial collaborators.

Lancet Oncol. 2017 Jun;18(6):755-769. doi: 10.1016/S1470-2045(17)30319-4. Epub 2017 May 4.

25.

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.

Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Gounaris I, Abraham JE, Hughes-Davies L, McAdam K, Chan S, Ahmad R, Hickish T, Rea D, Caldas C, Bartlett JMS, Cameron DA, Provenzano E, Thomas J, Hayward RL; ARTemis Investigators Group.

Ann Oncol. 2017 Aug 1;28(8):1817-1824. doi: 10.1093/annonc/mdx173.

26.

Impact assessment of WHO TobReg proposals for mandated lowering of selected mainstream cigarette smoke toxicants.

Eldridge AC, McAdam KG, Betson TR, Gama MV, Proctor CJ.

Regul Toxicol Pharmacol. 2017 Jun;86:332-348. doi: 10.1016/j.yrtph.2017.02.022. Epub 2017 Mar 8.

27.

E-cigarette Nicotine Delivery: Data and Learnings from Pharmacokinetic Studies.

Fearon IM, Eldridge A, Gale N, Shepperd CJ, McEwan M, Camacho OM, Nides M, McAdam K, Proctor CJ.

Am J Health Behav. 2017 Jan;41(1):16-32.

PMID:
27935787
28.

Trastuzumab-associated cardiac events in the Persephone trial.

Earl HM, Vallier AL, Dunn J, Loi S, Ogburn E, McAdam K, Hughes-Davies L, Harnett A, Abraham J, Wardley A, Cameron DA, Miles D, Gounaris I, Plummer C, Hiller L.

Br J Cancer. 2016 Dec 6;115(12):1462-1470. doi: 10.1038/bjc.2016.357. Epub 2016 Nov 22.

29.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS.

Br J Cancer. 2016 Oct 25;115(9):e16. doi: 10.1038/bjc.2016.342. Epub 2016 Oct 11. No abstract available.

30.

Chemical Composition of Aerosol from an E-Cigarette: A Quantitative Comparison with Cigarette Smoke.

Margham J, McAdam K, Forster M, Liu C, Wright C, Mariner D, Proctor C.

Chem Res Toxicol. 2016 Oct 17;29(10):1662-1678. Epub 2016 Sep 18.

31.

Influence of cigarette circumference on smoke chemistry, biological activity, and smoking behaviour.

McAdam K, Eldridge A, Fearon IM, Liu C, Manson A, Murphy J, Porter A.

Regul Toxicol Pharmacol. 2016 Dec;82:111-126. doi: 10.1016/j.yrtph.2016.09.010. Epub 2016 Sep 12. Review.

32.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS.

Br J Cancer. 2016 Sep 27;115(7):789-96. doi: 10.1038/bjc.2016.271. Epub 2016 Sep 6. Erratum in: Br J Cancer. 2016 Oct 25;115(9):e16.

33.

Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.

Ali HR, Dariush A, Provenzano E, Bardwell H, Abraham JE, Iddawela M, Vallier AL, Hiller L, Dunn JA, Bowden SJ, Hickish T, McAdam K, Houston S, Irwin MJ, Pharoah PD, Brenton JD, Walton NA, Earl HM, Caldas C.

Breast Cancer Res. 2016 Feb 16;18(1):21. doi: 10.1186/s13058-016-0682-8.

34.

The acrylamide content of smokeless tobacco products.

McAdam K, Kimpton H, Vas C, Rushforth D, Porter A, Rodu B.

Chem Cent J. 2015 Oct 12;9:56. doi: 10.1186/s13065-015-0132-1. eCollection 2015.

35.

Empirical characterisation of ranges of mainstream smoke toxicant yields from contemporary cigarette products using quantile regression methodology.

Camacho OM, Eldridge A, Proctor CJ, McAdam K.

Regul Toxicol Pharmacol. 2015 Aug;72(3):458-72. doi: 10.1016/j.yrtph.2015.05.023. Epub 2015 May 27.

36.

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.

Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Abraham J, Thomas J, Provenzano E, Hughes-Davies L, Gounaris I, McAdam K, Chan S, Ahmad R, Hickish T, Houston S, Rea D, Bartlett J, Caldas C, Cameron DA, Hayward L; ARTemis Investigators.

Lancet Oncol. 2015 Jun;16(6):656-66. doi: 10.1016/S1470-2045(15)70137-3. Epub 2015 May 11.

37.

An experimental method to study emissions from heated tobacco between 100-200°C.

Forster M, Liu C, Duke MG, McAdam KG, Proctor CJ.

Chem Cent J. 2015 Apr 16;9:20. doi: 10.1186/s13065-015-0096-1. eCollection 2015.

38.

Analysis of hydrazine in smokeless tobacco products by gas chromatography-mass spectrometry.

McAdam K, Kimpton H, Essen S, Davis P, Vas C, Wright C, Porter A, Rodu B.

Chem Cent J. 2015 Mar 16;9:13. doi: 10.1186/s13065-015-0089-0. eCollection 2015.

39.

High-resolution time and spatial imaging of tobacco and its pyrolysis products during a cigarette puff by microprobe sampling photoionisation mass spectrometry.

Hertz-Schünemann R, Ehlert S, Streibel T, Liu C, McAdam K, Baker RR, Zimmermann R.

Anal Bioanal Chem. 2015 Mar;407(8):2293-9. doi: 10.1007/s00216-014-8447-7. Epub 2015 Jan 28.

PMID:
25627787
40.

Variation in tobacco and mainstream smoke toxicant yields from selected commercial cigarette products.

Eldridge A, Betson TR, Gama MV, McAdam K.

Regul Toxicol Pharmacol. 2015 Apr;71(3):409-27. doi: 10.1016/j.yrtph.2015.01.006. Epub 2015 Jan 22.

41.

Highly time-resolved imaging of combustion and pyrolysis product concentrations in solid fuel combustion: NO formation in a burning cigarette.

Zimmermann R, Hertz-Schünemann R, Ehlert S, Liu C, McAdam K, Baker R, Streibel T.

Anal Chem. 2015 Feb 3;87(3):1711-7. doi: 10.1021/ac503512a. Epub 2015 Jan 12.

PMID:
25582882
42.

Multivariate analysis of mainstream tobacco smoke particulate phase by headspace solid-phase micro extraction coupled with comprehensive two-dimensional gas chromatography-time-of-flight mass spectrometry.

Brokl M, Bishop L, Wright CG, Liu C, McAdam K, Focant JF.

J Chromatogr A. 2014 Nov 28;1370:216-29. doi: 10.1016/j.chroma.2014.10.057. Epub 2014 Oct 24.

43.

Approaches for the design of reduced toxicant emission cigarettes.

Dittrich DJ, Fieblekorn RT, Bevan MJ, Rushforth D, Murphy JJ, Ashley M, McAdam KG, Liu C, Proctor CJ.

Springerplus. 2014 Jul 22;3:374. doi: 10.1186/2193-1801-3-374. eCollection 2014.

44.

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T, Cunningham D, Falk S, Wadd N, Harrison M, Corrie P, Iveson T, Robinson A, McAdam K, Eatock M, Evans J, Archer C, Hickish T, Garcia-Alonso A, Nicolson M, Steward W, Anthoney A, Greenhalf W, Shaw V, Costello E, Naisbitt D, Rawcliffe C, Nanson G, Neoptolemos J.

Lancet Oncol. 2014 Jul;15(8):829-40. doi: 10.1016/S1470-2045(14)70236-0. Epub 2014 Jun 19.

PMID:
24954781
45.

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.

Earl HM, Vallier AL, Hiller L, Fenwick N, Young J, Iddawela M, Abraham J, Hughes-Davies L, Gounaris I, McAdam K, Houston S, Hickish T, Skene A, Chan S, Dean S, Ritchie D, Laing R, Harries M, Gallagher C, Wishart G, Dunn J, Provenzano E, Caldas C; Neo-tAnGo Investigators.

Lancet Oncol. 2014 Feb;15(2):201-12. doi: 10.1016/S1470-2045(13)70554-0. Epub 2013 Dec 19.

46.

Trastuzumab beyond progression in advanced breast cancer: national guidance versus oncologist's decision.

Wong HH, Collins J, McAdam K, Wilson C.

Oncology. 2014;86(1):22-3. doi: 10.1159/000356876. Epub 2013 Dec 10. No abstract available.

PMID:
24335099
47.

Polycyclic aromatic hydrocarbons in US and Swedish smokeless tobacco products.

McAdam KG, Faizi A, Kimpton H, Porter A, Rodu B.

Chem Cent J. 2013 Sep 8;7(1):151. doi: 10.1186/1752-153X-7-151.

48.

Multi-analyte approach for determining the extraction of tobacco constituents from pouched snus by consumers during use.

Digard H, Gale N, Errington G, Peters N, McAdam K.

Chem Cent J. 2013 Apr 2;7(1):55. doi: 10.1186/1752-153X-7-55.

49.

The in vitro cytotoxicity and genotoxicity of cigarette smoke particulate matter with reduced toxicant yields.

Combes R, Scott K, Crooks I, Dillon D, Meredith C, McAdam K, Proctor C.

Toxicol In Vitro. 2013 Aug;27(5):1533-41. doi: 10.1016/j.tiv.2013.03.005. Epub 2013 Mar 27.

50.

Changes in levels of biomarkers of exposure observed in a controlled study of smokers switched from conventional to reduced toxicant prototype cigarettes.

Shepperd CJ, Eldridge A, Camacho OM, McAdam K, Proctor CJ, Meyer I.

Regul Toxicol Pharmacol. 2013 Jun;66(1):147-62. doi: 10.1016/j.yrtph.2013.02.007. Epub 2013 Mar 25. Erratum in: Regul Toxicol Pharmacol. 2013 Dec;67(3):536.

Supplemental Content

Loading ...
Support Center